Keros Therapeutics, Inc. (KROS)

NGM – Real Time Price. Currency in USD

10.88

+0.24 (2.26%)

Market open: Aug 12, 2026, 2:00 PM EDT

10.64

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

04.08.2026

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.

03.08.2026

Keros Therapeutics Reports Second Quarter 2026 Financial Results

LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended June 30, 2026.

Videos

No Data

There is no data to display

Press releases

03.08.2026

Keros Therapeutics, Inc. (KROS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Keros Therapeutics, Inc. (KROS)

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Keros Therapeutics Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

Keros Therapeutics Reports Second Quarter 2026 Financial Results

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Keros Therapeutics Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

Keros Therapeutics Reports Second Quarter 2026 Financial Results

Search stocks

Keros Therapeutics, Inc. (KROS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Keros Therapeutics, Inc. (KROS)

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Keros Therapeutics Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

Keros Therapeutics Reports Second Quarter 2026 Financial Results

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Keros Therapeutics Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

Keros Therapeutics Reports Second Quarter 2026 Financial Results